Table 2 Baseline and 12-week post-treatment metabolic and endocrine parameters
MET (n = 13) | LIRA (n = 14) | ROF (n = 14) | P values | ||||
|---|---|---|---|---|---|---|---|
Baseline | After therapy | Baseline | After therapy | Baseline | After therapy | ||
Glu 0 min OGTT (mmol/L) | 4.8 ± 0.9 | 4.4 ± 1.6 | 5.1 ± 1.1 | 4.7 ± 0.7 | 5.1 ± 0.5 | 5.0 ± 0.4 | I (L = 0.048) |
Insulin 0 min OGTT (mU/L) | 15.5 ± 6.0 | 12.7 ± 7.0 | 16 ± 9.3 | 14.5 ± 9.4 | 21.0 ± 7.7 | 21.0 ± 8.7 | NS |
HOMA-IR | 3.3 ± 1.2 | 2.5 ± 1.9 | 3.8 ± 2.8 | 3.2 ± 2.4 | 4.5 ± 1.7 | 4.6 ± 2.1 | NS |
Total T (nmol/L) | 1.7 ± 1.1 | 1.5 ± 1.2 | 1.7 ± 0.7 | 1.5 ± 0.6 | 1.8 ± 0.5 | 1.5 ± 0.6 | I (R = 0.050) |
Free T (nmol/L) | 3.6 ± 2.6 | 4.3 ± 3.0 | 3.7 ± 2.0 | 3.2 ± 2.0 | 4.0 ± 2.2 | 4.0 ± 2.3 | NS |
SHBG (nmol/L) | 28.6 ± 11.1 | 31.5 ± 5.6 | 30.5 ± 9.9 | 32.8 ± 14.2 | 27.0 ± 11.4 | 29.1 ± 12.1 | NS |
FAI | 7.6 ± 8.0 | 4.8 ± 3.6 | 6.5 ± 3.7 | 5.4 ± 2.9 | 8.3 ± 5.9 | 6.1 ± 4.6 | I (R = 0.016) |
Androstenedione (nmol/L) | 8.9 ± 3.8 | 10.7 ± 7.0 | 8.7 ± 3.4 | 9.0 ± 3.9 | 9.5 ± 2.5 | 9.4 ± 3.9 | NS |
DHEA-S (μmol/L) | 5.9 ± 2.5 | 6.8 ± 3.5 | 6.6 ± 3.3 | 6.1 ± 2.4 | 5.6 ± 2.7 | 5.2 ± 1.9 | NS |